SCHEMBL30206126

SCHEMBL30206126

COc1nc(Nc2ccc(N3CCOCC3)cc2)c(C(N)=O)nc1-c1cccc2c1ncn2C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EML4 Q9HC35 4/20 0.44
▸ ALK Q9UM73 4/20 0.44
▸ STAT6 P42226 2/20 0.43
▸ LCK P06239 1/20 0.42
▸ JAK3 P52333 1/20 0.42
▸ CSF1R P07333 2/20 0.42
▸ CCNA2 P20248 2/20 0.42
▸ CDK2 P24941 2/20 0.42
▸ RET P07949 2/20 0.42
▸ ROS1 P08922 2/20 0.42
▸ FLT3 P36888 2/20 0.42
▸ AURKA O14965 1/20 0.42
▸ CDK4 P11802 1/20 0.42
▸ CCND3 P30281 1/20 0.42
▸ CDK6 Q00534 1/20 0.42
▸ EGFR P00533 3/20 0.40
▸ SYK P43405 2/20 0.40
▸ CCNA1 P78396 1/20 0.40
▸ PKMYT1 Q99640 1/20 0.40
▸ MAPK10 P53779 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24944375 1.00 EML4 (0.44) EML4ALKSTAT6LCKJAK3
SCHEMBL29173355 0.93 PKMYT1 (0.40) STAT6LCKJAK3CSF1REGFR
SCHEMBL30206236 0.93 PKMYT1 (0.40) STAT6LCKJAK3CSF1REGFR
SCHEMBL24944946 0.90 EML4 (0.46) EML4ALKSTAT6JAK3CCNA2
SCHEMBL30205485 0.90 LCK (0.43) EML4ALKSTAT6LCKJAK3
SCHEMBL24944389 0.90 LCK (0.43) EML4ALKSTAT6LCKJAK3
SCHEMBL24944396 0.90 EML4 (0.46) EML4ALKSTAT6LCKJAK3
SCHEMBL24943804 0.90 EML4 (0.46) EML4ALKSTAT6LCKJAK3
SCHEMBL30206083 0.90 EML4 (0.46) EML4ALKSTAT6LCKJAK3
SCHEMBL30205573 0.90 EML4 (0.46) EML4ALKSTAT6LCKJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP claimed
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2024-11-14 — — US claimed
CN-117693503-A Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer 阿斯利康(瑞典)有限公司 2024-03-12 — — CN claimed
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP disclosed
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2024-11-14 — — US disclosed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP disclosed
CN-117693503-A Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer 阿斯利康(瑞典)有限公司 2024-03-12 — — CN disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PDXK, PGK1, PGK2 EML4 2189/4885ALK 2002/4885STAT6 1453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback